Thread by @cdenki

We just published as preprint our RCT on convalescent and vaccinated plasma.
Importantly the trial showed that in a selected group of patients with hematological and oncological malignancies, SARS-Cov-2 antibody containing plasma is a effective medrxiv.org/content/10.110…

In fact, it not only reduced time to discharge from the hospital (primary endpoint) but also survival (secondary endpoint). While these results should be confirmed in a separate study, the effect size is convincing.

Note that the study confirmed findings of other studies, that showed no effect in unselected elderly patients and patients with laboratory findings suggesting higher risk of severe disease.

Titers of neutralizing antibodies increase in patients with cancer only in response to plasma while in other groups they increase even without plasma donation. Thus suggesting a pathophysiological explanation of the clinical findings.

These results come at a time, when monoclonal antibodies are no longer effective in these patients and other treatment options are often limited due to drug-drug interactions and other reasons.

Thus these results suggests that especially high titer Ideally hybrid convalescent/vaccinated plasma which is easily accessible could provide a treatment option for these vulnerable patients who often are not sufficiently protected by vaccination

#plasma
#treatment
#COVID
#Cancer

@CasaValli
@COVID19nCCC
@DrJLHenderson
@mvankerkhove
@LabTidow
@mugecevik
And thank you to the many contributors and patients who made this study possible